HRA Tracking Changes to CMS Innovation Center

April 1, 2025 – Following a comprehensive review of its portfolio, CMS identified several models that it believes do not meet its statutory requirements or strategic goals. As a result, several models will conclude at the end of CY 2025—prior to their originally scheduled end dates.

Additionally, CMS announced it will no longer move forward with implementing the Medicare $2 Drug List Model or its Accelerating Clinical Evidence model, both of which were developed in response to Executive Order 14087, which was rescinded under the current Administration.

Finally, CMS reported that it plans to announce a new strategy for the Innovation Center “based on guiding principles to make Americans healthier by preventing disease through evidence-based practices, empowering people with information to make better decisions, and driving choice and competition.”

HRA will continue to monitor and keep its membership informed on developments around the CMS Innovation Center as more information becomes available.